Paclitaxel induces vascular endothelial growth factor expression through reactive oxygen species production

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Paclitaxel, an antineoplastic drug, targets cancer cells by stabilizing microtubules and arresting the cell cycle at G2/M phase.
• Paclitaxel resistance in tumors poses a significant challenge to effective cancer therapy.
• Vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1 (HIF-1) are key regulators of tumor neovascularization, with HIF-1 controlling VEGF transcription.

Purpose of the Study:

• To investigate the effect of paclitaxel treatment on VEGF expression.
• To elucidate the mechanisms underlying paclitaxel-induced VEGF modulation.
• To explore the role of reactive oxygen species (ROS) and associated signaling pathways in paclitaxel resistance.

Main Methods:

• Dose-dependent cell death assays were performed following paclitaxel treatment.
• VEGF expression levels were quantified.
• Activation of nuclear factor-kappaB (NF-κB) and stabilization of HIF-1α were assessed.
• Luciferase activity assays were used to evaluate HIF-1α response elements on the VEGF gene.
• The role of ROS was investigated using hydrogen peroxide (H2O2) and ROS scavengers.

Main Results:

• Paclitaxel treatment led to dose-dependent cancer cell death and elevated VEGF expression.
• Paclitaxel induced NF-κB activation and HIF-1α stabilization, enhancing VEGF gene activity.
• Paclitaxel generated ROS, which were implicated in increased VEGF expression.
• ROS scavengers reduced paclitaxel-induced VEGF expression and aggravated paclitaxel-induced cell death.

Conclusions:

• Paclitaxel-induced VEGF expression is likely mediated by ROS production.
• NF-κB activation and HIF-1α stabilization are key pathways in this process.
• Understanding these mechanisms may offer strategies to overcome paclitaxel resistance in cancer treatment.